Zhang Geng, Zhang Ying, Wang Cong, Zhou Chenhe, Yan Shigui
Department of Orthopedic Surgery, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Department of Orthopedic Surgery, Taizhou Hospital of Traditional Chinese Medicine, Taizhou, China.
Evid Based Complement Alternat Med. 2022 Jun 10;2022:6065494. doi: 10.1155/2022/6065494. eCollection 2022.
Postmenopausal osteoporosis is a metabolic disease caused by an imbalance between osteoclasts and osteoblasts. At present, the drug strategy for treating postmenopausal osteoporosis has some limitations and is unable to satisfy the demands of patients. is an herbal extract from , with an inhibitory effect on osteolysis. In this study, we described the role of in ovariectomy-induced osteoporosis and its effect on osteoclast differentiation . Eighteen female C57BL/6 mice were randomly divided into three groups: sham group (sham surgery and injection with 0.9% normal saline), ovariectomized group (ovariectomy and injection with 0.9% normal saline), and group (ovariectomy and injecting with 100 mg/kg for 2 days). Mice were sacrificed after 6-week administration and femurs were harvested for microcomputed tomography (micro-CT) and histomorphology analyses. In vitro, we used different concentrations of to study its effect on osteoclastogenesis. The results showed that the BV/TV, Tb.Th, and Tb.N in trabecular bone were increased in the group compared with the OVX group, and the trabecular bone mass was remarkably decreased in the OVX group compared with the sham group. The number of osteoclasts was increased in the OVX group compared to the sham group, and the number and area of osteoclasts were decreased in the group compared to the control group. Compared with the OVX group, the number and area of osteoclasts were reduced in the group. In conclusion, could inhibit the formation of osteoclasts, promote the growth of bone trabecular, and relieve osteoporosis caused by ovariectomy, with a certain clinical adoption value.
绝经后骨质疏松症是一种由破骨细胞和成骨细胞之间失衡引起的代谢性疾病。目前，治疗绝经后骨质疏松症的药物策略存在一些局限性，无法满足患者的需求。[药物名称]是一种从[植物名称]中提取的草药提取物，对骨溶解具有抑制作用。在本研究中，我们描述了[药物名称]在去卵巢诱导的骨质疏松症中的作用及其对破骨细胞分化的影响。18只雌性C57BL/6小鼠随机分为三组：假手术组（假手术并注射0.9%生理盐水）、去卵巢组（去卵巢并注射0.9%生理盐水）和[药物名称]组（去卵巢并注射100mg/kg[药物名称]，持续2天）。给药6周后处死小鼠，收集股骨进行显微计算机断层扫描（micro-CT）和组织形态学分析。在体外，我们使用不同浓度的[药物名称]来研究其对破骨细胞形成的影响。结果显示，与去卵巢组相比，[药物名称]组小梁骨的骨体积分数（BV/TV）、骨小梁厚度（Tb.Th）和骨小梁数量（Tb.N）增加，而去卵巢组与假手术组相比，小梁骨量显著减少。与假手术组相比，去卵巢组破骨细胞数量增加，与对照组相比，[药物名称]组破骨细胞数量和面积减少。与去卵巢组相比，[药物名称]组破骨细胞数量和面积减少。综上所述，[药物名称]可抑制破骨细胞形成，促进骨小梁生长，缓解去卵巢所致的骨质疏松症，具有一定的临床应用价值。
